Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

[Therapy resistant diabetes mellitus and lipodystrophy: leptin therapy leads to improvement].

Jazet IM, Jonker JT, Wijngaarden MA, Lamb H, Smelt AH.

Ned Tijdschr Geneeskd. 2013;157(4):A5482. Review. Dutch.

PMID:
23343738
2.

Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.

Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, Cline GW, DePaoli AM, Taylor SI, Gorden P, Shulman GI.

J Clin Invest. 2002 May;109(10):1345-50.

3.

Leptin-replacement therapy for lipodystrophy.

Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A.

N Engl J Med. 2002 Feb 21;346(8):570-8.

4.

Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy.

Park JY, Chong AY, Cochran EK, Kleiner DE, Haller MJ, Schatz DA, Gorden P.

J Clin Endocrinol Metab. 2008 Jan;93(1):26-31. Epub 2007 Oct 16.

5.

Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience.

Araujo-Vilar D, Sánchez-Iglesias S, Guillín-Amarelle C, Castro A, Lage M, Pazos M, Rial JM, Blasco J, Guillén-Navarro E, Domingo-Jiménez R, del Campo MR, González-Méndez B, Casanueva FF.

Endocrine. 2015 May;49(1):139-47. doi: 10.1007/s12020-014-0450-4. Epub 2014 Nov 4.

6.

Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.

Diker-Cohen T, Cochran E, Gorden P, Brown RJ.

J Clin Endocrinol Metab. 2015 May;100(5):1802-10. doi: 10.1210/jc.2014-4491. Epub 2015 Mar 3.

7.

Metabolic correction induced by leptin replacement treatment in young children with Berardinelli-Seip congenital lipoatrophy.

Beltrand J, Beregszaszi M, Chevenne D, Sebag G, De Kerdanet M, Huet F, Polak M, Tubiana-Rufi N, Lacombe D, De Paoli AM, Levy-Marchal C.

Pediatrics. 2007 Aug;120(2):e291-6.

PMID:
17671040
8.

Long-term efficacy of leptin replacement in patients with generalized lipodystrophy.

Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Gorden P.

Diabetes. 2005 Jul;54(7):1994-2002.

9.

[Difficult to manage diabetes mellitus associated with generalized congenital lipodystrophy. Report of two cases].

Cardona-Hernández R, Suárez-Ortega L, Torres M.

An Pediatr (Barc). 2011 Feb;74(2):126-30. doi: 10.1016/j.anpedi.2010.09.020. Epub 2010 Dec 17. Spanish.

10.
11.

Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.

Ebihara K, Kusakabe T, Hirata M, Masuzaki H, Miyanaga F, Kobayashi N, Tanaka T, Chusho H, Miyazawa T, Hayashi T, Hosoda K, Ogawa Y, DePaoli AM, Fukushima M, Nakao K.

J Clin Endocrinol Metab. 2007 Feb;92(2):532-41. Epub 2006 Nov 21.

PMID:
17118991
12.

Leptin replacement therapy for the treatment of non-HAART associated lipodystrophy syndromes: a meta-analysis into the effects of leptin on metabolic and hepatic endpoints.

Rodríguez AJ, Neeman T, Giles AG, Mastronardi CA, Paz Filho G.

Arq Bras Endocrinol Metabol. 2014 Nov;58(8):783-97. Epub 2014 Nov 1. Review.

13.

The liver diseases of lipodystrophy: the long-term effect of leptin treatment.

Safar Zadeh E, Lungu AO, Cochran EK, Brown RJ, Ghany MG, Heller T, Kleiner DE, Gorden P.

J Hepatol. 2013 Jul;59(1):131-7. doi: 10.1016/j.jhep.2013.02.007. Epub 2013 Feb 21.

14.

Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.

Chan JL, Lutz K, Cochran E, Huang W, Peters Y, Weyer C, Gorden P.

Endocr Pract. 2011 Nov-Dec;17(6):922-32. doi: 10.4158/EP11229.OR.

15.

Insulin resistance, acanthosis nigricans, and hypertriglyceridemia.

Eberting CL, Javor E, Gorden P, Turner ML, Cowen EW.

J Am Acad Dermatol. 2005 Feb;52(2):341-4. No abstract available.

PMID:
15692481
16.

Effects of Metreleptin in Pediatric Patients With Lipodystrophy.

Brown RJ, Meehan CA, Cochran E, Rother KI, Kleiner DE, Walter M, Gorden P.

J Clin Endocrinol Metab. 2017 May 1;102(5):1511-1519. doi: 10.1210/jc.2016-3628.

PMID:
28324110
17.

The clinical efficacy of the adipocyte-derived hormone leptin in metabolic dysfunction.

Gorden P, Park JY.

Arch Physiol Biochem. 2006 Apr;112(2):114-8. Review.

PMID:
16931453
18.

Inherited lipodystrophies and hypertriglyceridemia.

Simha V, Garg A.

Curr Opin Lipidol. 2009 Aug;20(4):300-8. doi: 10.1097/MOL.0b013e32832d4a33. Review.

PMID:
19494770
19.

Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.

Meehan CA, Cochran E, Kassai A, Brown RJ, Gorden P.

Expert Rev Clin Pharmacol. 2016;9(1):59-68. doi: 10.1586/17512433.2016.1096772. Epub 2015 Oct 14. Review.

20.

Leptin activates hepatic 5'-AMP-activated protein kinase through sympathetic nervous system and α1-adrenergic receptor: a potential mechanism for improvement of fatty liver in lipodystrophy by leptin.

Miyamoto L, Ebihara K, Kusakabe T, Aotani D, Yamamoto-Kataoka S, Sakai T, Aizawa-Abe M, Yamamoto Y, Fujikura J, Hayashi T, Hosoda K, Nakao K.

J Biol Chem. 2012 Nov 23;287(48):40441-7. doi: 10.1074/jbc.M112.384545. Epub 2012 Sep 28.

Supplemental Content

Support Center